{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T07:47:09Z","timestamp":1782719229229,"version":"3.54.5"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T00:00:00Z","timestamp":1774051200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T00:00:00Z","timestamp":1774051200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Jpn J Radiol"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>\n                      This study was conducted to examine relationships of pretreatment volume-based quantitative\n                      <jats:sup>18<\/jats:sup>\n                      F-fluorodeoxyglucose (\n                      <jats:sup>18<\/jats:sup>\n                      F-FDG) positron emission tomography\/computed tomography (PET\/CT) parameters with overall survival (OS) in malignant peritoneal mesothelioma (MPeM) patients.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>\n                      Data for 71 patients with FDG-avid MPeM who underwent pretreatment\n                      <jats:sup>18<\/jats:sup>\n                      F-FDG PET\/CT were retrospectively reviewed. The highest maximum standardized uptake value (SUVmax), metabolic tumor volume (WB MTV), and total lesion glycolysis (WB TLG) were calculated, including primary tumors and metastatic lesions. Relationships of clinicopathological factors (histological subtype, primary peritoneal disease form, abdominal nodal metastasis, extra-abdominal metastasis, treatment regimen), as well as volume-based quantitative PET\/CT parameters with OS were evaluated using a Cox proportional hazards model and log-rank test.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Enrolled patients underwent follow-up for a mean period of 27.6\u00a0months (range 2.1\u2013161.2\u00a0months, median 18.9\u00a0months), during which 49 (69.0%) died. Receiver operating characteristic curve analysis and log-rank testing indicated that those with high SUVmax (\u2265\u20096.9), WB MTV (\u2265\u200960), or WB TLG (\u2265\u2009230) had a significantly lower OS rate than patients with a low rate (&lt;\u20096.9,\u2009&lt;\u200960,\u2009&lt;\u2009230; p\u2009=\u20090.0002, p\u2009&lt;\u20090.0001, p\u2009&lt;\u20090.0001, respectively). Univariate analysis of all patients indicated an association of diffuse peritoneal disease form (p\u2009=\u20090.022), high level SUVmax (p\u2009=\u20090.0002), WB MTV (p\u2009&lt;\u20090.0001), or WB TLG (p\u2009&lt;\u20090.0001) level, extra-abdominal metastasis (p\u2009=\u20090.079) and treatment regimen (p\u2009=\u20090.058) with significantly shorter OS. Additionally, multivariate analysis results confirmed high WB MTV as an independent negative predictor (hazard ratio 2.51, 95% confidence interval 0.72\u201313.45; p\u2009=\u20090.039).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      These findings indicate that pretreatment volume-based quantitative\n                      <jats:sup>18<\/jats:sup>\n                      F-FDG PET\/CT parameters, especially whole-body MTV, may be useful as surrogate markers for MPeM prognosis.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11604-026-01977-9","type":"journal-article","created":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T05:59:47Z","timestamp":1774072787000},"page":"1257-1262","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pretreatment volume-based 18F-FDG PET\/CT parameters as prognostic indicators in malignant peritoneal mesothelioma patients"],"prefix":"10.1007","volume":"44","author":[{"given":"Kazuhiro","family":"Kitajima","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosuke","family":"Matsuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Yokoyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiyuki","family":"Minami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akifumi","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kozo","family":"Kuribayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Kijima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichiro","family":"Yamakado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,21]]},"reference":[{"issue":"11","key":"1977_CR1","doi-asserted-by":"publisher","first-page":"236","DOI":"10.21037\/atm.2017.03.96","volume":"5","author":"J Kim","year":"2017","unstructured":"Kim J, Bhagwandin S, Labow DM. Malignant peritoneal mesothelioma: a review. Ann Transl Med. 2017;5(11):236. https:\/\/doi.org\/10.21037\/atm.2017.03.96.","journal-title":"Ann Transl Med"},{"issue":"1","key":"1977_CR2","doi-asserted-by":"publisher","first-page":"38","DOI":"10.4240\/wjgs.v1.i1.38","volume":"1","author":"S Munkholm-Larsen","year":"2009","unstructured":"Munkholm-Larsen S, Cao CQ, Yan TD. Malignant peritoneal mesothelioma. World J Gastrointest Surg. 2009;1(1):38\u201348. https:\/\/doi.org\/10.4240\/wjgs.v1.i1.38.","journal-title":"World J Gastrointest Surg"},{"issue":"4","key":"1977_CR3","doi-asserted-by":"publisher","first-page":"433","DOI":"10.4149\/neo_2014_053","volume":"61","author":"H Kaya","year":"2014","unstructured":"Kaya H, Sezg\u0131 C, Tanr\u0131kulu AC, Taylan M, Abakay O, Sen HS, et al. Prognostic factors influencing survival in 35 patients with malignant peritoneal mesothelioma. Neoplasma. 2014;61(4):433\u20138. https:\/\/doi.org\/10.4149\/neo_2014_053.","journal-title":"Neoplasma"},{"issue":"8","key":"1977_CR4","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1007\/s00259-015-3037-2","volume":"42","author":"K Kitajima","year":"2015","unstructured":"Kitajima K, Suenaga Y, Ueno Y, Maeda T, Ebina Y, Yamada H, et al. Preoperative risk stratification using metabolic parameters of 18F-FDG PET\/CT in patients with endometrial cancer. Eur J Nucl Med Mol Imaging. 2015;42(8):1268\u201375. https:\/\/doi.org\/10.1007\/s00259-015-3037-2.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1977_CR5","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.ejrad.2016.11.019","volume":"86","author":"K Kitajima","year":"2017","unstructured":"Kitajima K, Doi H, Kuribayashi K, Hashimoto M, Tsuchitani T, Tanooka M, et al. Prognostic value of pretreatment volume-based quantitative 18F-FDG PET\/CT parameters in patients with malignant pleural mesothelioma. Eur J Radiol. 2017;86:176\u201383. https:\/\/doi.org\/10.1016\/j.ejrad.2016.11.019.","journal-title":"Eur J Radiol"},{"key":"1977_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/s13550-018-0438-9","volume":"8","author":"Y Tsutsui","year":"2018","unstructured":"Tsutsui Y, Daisaki H, Akamatsu G, Umeda T, Ogawa M, Kajiwara H, et al. Multicentre analysis of PET SUV using vendor-neutral software: the Japanese harmonization technology (J-Hart) study. EJNMMI Res. 2018;8:83. https:\/\/doi.org\/10.1186\/s13550-018-0438-9.","journal-title":"EJNMMI Res"},{"issue":"1","key":"1977_CR7","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/s00468177(77)80067-1","volume":"8","author":"M Kannerstein","year":"1977","unstructured":"Kannerstein M, Churg J. Peritoneal mesothelioma. Hum Pathol. 1977;8(1):83\u201394. https:\/\/doi.org\/10.1016\/s00468177(77)80067-1.","journal-title":"Hum Pathol"},{"issue":"2","key":"1977_CR8","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/S0016-5085(19)33323-2","volume":"63","author":"CG Moertel","year":"1972","unstructured":"Moertel CG. Peritoneal mesothelioma. Gastroenterology. 1972;63(2):346\u201350.","journal-title":"Gastroenterology"},{"issue":"6","key":"1977_CR9","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.ctrv.2012.12.005","volume":"39","author":"J Remon","year":"2013","unstructured":"Remon J, Lianes P, Mart\u00ednez S, Velasco M, Querol R, Zanui M. Malignant mesothelioma: new insights into a rare disease. Cancer Treat Rev. 2013;39(6):584\u201391. https:\/\/doi.org\/10.1016\/j.ctrv.2012.12.005.","journal-title":"Cancer Treat Rev"},{"issue":"4","key":"1977_CR10","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1002\/jso.21055","volume":"98","author":"M Deraco","year":"2008","unstructured":"Deraco M, Bartlett D, Kusamura S, Baratti D. Consensus statement on peritoneal mesothelioma. J Surg Oncol. 2008;98(4):268\u201372. https:\/\/doi.org\/10.1002\/jso.21055.","journal-title":"J Surg Oncol"},{"key":"1977_CR11","doi-asserted-by":"publisher","first-page":"4231","DOI":"10.2147\/CMAR.S170300","volume":"11","author":"LM Enomoto","year":"2019","unstructured":"Enomoto LM, Shen P, Levine EA, Votanopoulos KI. Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for peritoneal mesothelioma: patient selection and special considerations. Cancer Manag Res. 2019;11:4231\u201341. https:\/\/doi.org\/10.2147\/CMAR.S170300.","journal-title":"Cancer Manag Res"},{"key":"1977_CR12","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/978-1-4613-1247-5_23","volume":"82","author":"P Jacquet","year":"1996","unstructured":"Jacquet P, Sugarbaker PH. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat Res. 1996;82:359\u201374. https:\/\/doi.org\/10.1007\/978-1-4613-1247-5_23.","journal-title":"Cancer Treat Res"},{"issue":"2","key":"1977_CR13","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.ejso.2010","volume":"37","author":"F Cavaliere","year":"2011","unstructured":"Cavaliere F, De Simone M, Virz\u00ec S, Deraco M, Rossi CR, Garofalo A, et al. Prognostic factors and oncologic outcome in 146 patients with colorectal peritoneal carcinomatosis treated with cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy: Italian multicenter study S.I.T.I.L.O. Eur J Surg Oncol. 2011;37(2):148\u201354. https:\/\/doi.org\/10.1016\/j.ejso.2010.","journal-title":"Eur J Surg Oncol"},{"issue":"5","key":"1977_CR14","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1245\/s10434-014-4041-7","volume":"22","author":"RN Low","year":"2015","unstructured":"Low RN, Barone RM, Lucero J. Comparison of MRI and CT for predicting the Peritoneal Cancer Index (PCI) preoperatively in patients being considered for cytoreductive surgical procedures. Ann Surg Oncol. 2015;22(5):1708\u201315. https:\/\/doi.org\/10.1245\/s10434-014-4041-7.","journal-title":"Ann Surg Oncol"}],"container-title":["Japanese Journal of Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11604-026-01977-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11604-026-01977-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11604-026-01977-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T07:16:05Z","timestamp":1782717365000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11604-026-01977-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,21]]},"references-count":14,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["1977"],"URL":"https:\/\/doi.org\/10.1007\/s11604-026-01977-9","relation":{},"ISSN":["1867-1071","1867-108X"],"issn-type":[{"value":"1867-1071","type":"print"},{"value":"1867-108X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,21]]},"assertion":[{"value":"13 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"We declare no financial support or relationship that may pose conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"We clearly state that human participants have the approval of an appropriate named ethics committee including Helsinki declaration.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"This retrospective study was approved by the institutional review board, and the need for patient informed consent was waived.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}]}}